These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 33793357)

  • 1. Immediate reaction to ibrutinib amenable to oral desensitization.
    Phadke NA; Luk SO; Hochberg EP; Banerji A
    J Oncol Pharm Pract; 2021 Oct; 27(7):1802-1805. PubMed ID: 33793357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Presentation and management of the delayed type of hypersensitivity reaction with bendamustine.
    Shikdar S; Totton D; Turco T; Rachshtut M
    Anticancer Drugs; 2018 Sep; 29(8):814-816. PubMed ID: 29877929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibrutinib-associated sever skin toxicity: A case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - Case report and literature review.
    Ghasoub R; Albattah A; Elazzazy S; Alokka R; Nemir A; Alhijji I; Taha R
    J Oncol Pharm Pract; 2020 Mar; 26(2):487-491. PubMed ID: 31216242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia.
    Hampel PJ; Call TG; Rabe KG; Ding W; Muchtar E; Kenderian SS; Wang Y; Leis JF; Witzig TE; Koehler AB; Fonder AL; Schwager SM; Van Dyke DL; Braggio E; Slager SL; Kay NE; Parikh SA
    Oncologist; 2020 Nov; 25(11):974-980. PubMed ID: 32886416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protocols for drug allergy desensitization in children.
    Diaferio L; Giovannini M; Clark E; Castagnoli R; Caimmi D
    Expert Rev Clin Immunol; 2020 Jan; 16(1):91-100. PubMed ID: 31771366
    [No Abstract]   [Full Text] [Related]  

  • 6. Ibrutinib treatment via alternative administration in a patient with chronic lymphocytic leukemia and dysphagia.
    DiSogra KY; Tran T; Arnall JR; Janes A; Moore DC; Park SI
    J Oncol Pharm Pract; 2021 Jul; 27(5):1265-1269. PubMed ID: 33106104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late onset left ventricular dysfunction and cardiomyopathy induced with ibrutinib.
    Gülsaran SK; Baysal M; Demirci U; Baş V; Kirkizlar HO; Umit E; Demir AM
    J Oncol Pharm Pract; 2020 Mar; 26(2):478-480. PubMed ID: 31142233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid desensitization of hypersensitivity reactions to chemotherapy agents.
    Castells M
    Curr Drug Saf; 2006 Aug; 1(3):243-51. PubMed ID: 18690934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute gout flare of bilateral first metatarsophalangeal joints due to ibrutinib use in chronic lymphocytic leukemia.
    Kaur J; Tuler S; Dasanu CA
    J Oncol Pharm Pract; 2022 Mar; 28(2):442-444. PubMed ID: 34225525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Transformation to Classic Hodgkin Lymphoma in a Chemotherapy-naïve Chronic Lymphocytic Leukemia Patient upon Initial Treatment with Ibrutinib.
    Koshiishi M; Odate T; Nakagawa Y; Suzuki J; Kumagai T; Kawashima I; Yamamoto T; Nakajima K; Tanaka M; Oishi N; Kondo T; Kirito K
    Intern Med; 2021 Oct; 60(20):3305-3308. PubMed ID: 33896865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Haemorrhagic complications following ibrutinib intake after dermatological surgery].
    Lebas D; Preta LH; Leguern A; Modiano P; Wiart T
    Ann Dermatol Venereol; 2020 Nov; 147(11):775-779. PubMed ID: 32917401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Desensitization to imatinib in patients with leukemia.
    Nelson RP; Cornetta K; Ward KE; Ramanuja S; Fausel C; Cripe LD
    Ann Allergy Asthma Immunol; 2006 Aug; 97(2):216-22. PubMed ID: 16937754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
    Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
    Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world ibrutinib dose reductions, holds and discontinuations in chronic lymphocytic leukemia.
    Hou JZ; Ryan K; Du S; Fang B; Marks S; Page R; Peng E; Szymanski K; Winters S; Le H
    Future Oncol; 2021 Dec; 17(35):4959-4969. PubMed ID: 34783255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Eyes Cannot See What the Mind Does Not Know: Endocrinological Side Effects of Ibrutinib.
    Chandrashekar N; McKenney R
    WMJ; 2020 Dec; 119(4):293-295. PubMed ID: 33428844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desensitization for hypersensitivity reactions to medications.
    del Carmen Sancho M; Breslow R; Sloane D; Castells M
    Chem Immunol Allergy; 2012; 97():217-33. PubMed ID: 22613865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Keeping a balance in chronic lymphocytic leukemia (CLL) patients taking ibrutinib: ibrutinib-associated adverse events and their management based on drug interactions.
    Cho HJ; Baek DW; Kim J; Lee JM; Moon JH; Sohn SK
    Expert Rev Hematol; 2021 Sep; 14(9):819-830. PubMed ID: 34375536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.
    Archibald WJ; Rabe KG; Kabat BF; Herrmann J; Ding W; Kay NE; Kenderian SS; Muchtar E; Leis JF; Wang Y; Chanan-Khan AA; Schwager SM; Koehler AB; Fonder AL; Slager SL; Shanafelt TD; Call TG; Parikh SA
    Ann Hematol; 2021 Jan; 100(1):143-155. PubMed ID: 32488603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Campylobacter infection in 4 patients treated with ibrutinib.
    Sorin B; Vigneron J; Fadlallah J; Mondesir J; Fieschi C; Oksenhendler E; Galicier L; Malphettes M
    Eur J Clin Microbiol Infect Dis; 2022 May; 41(5):849-852. PubMed ID: 35304678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clopidogrel Desensitization: Background and Recommendations for Use of a Rapid (4 Hour) Protocol.
    Bulva J; Simon RA
    Curr Vasc Pharmacol; 2019; 17(2):113-118. PubMed ID: 30378498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.